Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials

Documenti analoghi

• The effect of gantenerumab treatment on brain functional connectivity
  di: Susanna Gobbi, et al.
  Pubblicazione: (2024)
• Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease
  di: Stefan J. Teipel, et al.
  Pubblicazione: (2024)
• Longitudinal effects of gantenerumab treatment on amyloid‐PET‐derived perfusion estimates in an early AD population
  di: Erica Silvestri, et al.
  Pubblicazione: (2024)
• Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug
  di: Robyn Moxon, et al.
  Pubblicazione: (2025)
• Sick sinus syndrome and high‐degree atrioventricular block in dementia with Lewy bodies and other dementia subtypes: A study of ≈ 73,000 patients with dementia
  di: Isak Heyman, et al.
  Pubblicazione: (2025)